Aug 15, 2005
San Francisco-based Sirna Therapeutics, a clinical-stage biotech company developing RNAi-based therapies, completed the initial closing of a $28-million financing to support ongoing development of Sirna-027, a chemically modified siRNA to treat age-related macular degeneration.
The Mayo Clinic, in collaboration with the Translational Genomics Research Institute (TGen), has opened a biomedical scientific facility, the Mayo Clinic Collaborative Research Building, in Scottsdale, Ariz. The clinic says its work with TGen “signifies hope for those patients battling cancer.”
HistoRx, of New Haven, Conn., appointed Paul Stroobant, formerly of BG Medicine and Millennium Pharmaceuticals, as VP of research. HistoRx is introducing advanced quantitative diagnostic products for research and clinical pathology markets.
The Bill & Melinda Gates Foundation will share $437 million in grant money (five-year grants of up to $20 million each) with 43 project winners of a worldwide competition to find new ideas to attack global health challenges.